ATE277933T1 - Thiophenverbindungen zur verwendung als antikrebsmittel - Google Patents

Thiophenverbindungen zur verwendung als antikrebsmittel

Info

Publication number
ATE277933T1
ATE277933T1 AT01925786T AT01925786T ATE277933T1 AT E277933 T1 ATE277933 T1 AT E277933T1 AT 01925786 T AT01925786 T AT 01925786T AT 01925786 T AT01925786 T AT 01925786T AT E277933 T1 ATE277933 T1 AT E277933T1
Authority
AT
Austria
Prior art keywords
anticancer agents
thiophene compounds
thiophene
compounds
anticancer
Prior art date
Application number
AT01925786T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Matthew Arnold Marx
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE277933T1 publication Critical patent/ATE277933T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01925786T 2000-06-06 2001-05-02 Thiophenverbindungen zur verwendung als antikrebsmittel ATE277933T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20968600P 2000-06-06 2000-06-06
PCT/IB2001/000766 WO2001094353A1 (en) 2000-06-06 2001-05-02 Thiophene derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE277933T1 true ATE277933T1 (de) 2004-10-15

Family

ID=22779830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925786T ATE277933T1 (de) 2000-06-06 2001-05-02 Thiophenverbindungen zur verwendung als antikrebsmittel

Country Status (23)

Country Link
US (1) US6964961B2 (de)
EP (1) EP1287001B1 (de)
JP (1) JP2003535867A (de)
AR (1) AR032621A1 (de)
AT (1) ATE277933T1 (de)
AU (1) AU2001252463A1 (de)
BR (1) BR0111377A (de)
CA (1) CA2411084A1 (de)
DE (1) DE60106022T2 (de)
DO (1) DOP2001000170A (de)
EC (1) ECSP014097A (de)
ES (1) ES2223827T3 (de)
GT (1) GT200100104A (de)
MX (1) MXPA02012034A (de)
PA (1) PA8518701A1 (de)
PE (1) PE20011373A1 (de)
PT (1) PT1287001E (de)
PY (1) PY0111330A (de)
SV (1) SV2002000478A (de)
TN (1) TNSN01082A1 (de)
TR (1) TR200402656T4 (de)
UY (1) UY26750A1 (de)
WO (1) WO2001094353A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377771A1 (en) * 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
WO2002012227A2 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
PL371435A1 (en) * 2002-02-01 2005-06-13 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
BR0308162A (pt) * 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
HRP20041154A2 (en) * 2002-06-06 2005-06-30 Boehringer Ingelheim Pharmaceuticals Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
DK1904504T3 (da) 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
NZ564283A (en) 2005-05-20 2011-07-29 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 erbb 유형 i 수용체티로신 키나제 억제제로서의 n4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
EP1989211A2 (de) * 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterocyclische thiophenverbindungen und verfahren zu ihrer verwendung
MX2009010517A (es) 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
NZ588355A (en) 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
EP3461481A1 (de) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Verfahren zur aufrechterhaltung, behandlung oder verbesserung der kognitiven funktion
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CN113648307B (zh) * 2021-09-23 2022-09-30 河南大学 MII-tt-DTT及其在制备抗结直肠癌药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071227B1 (de) 1981-07-31 1987-11-11 Sloan-Kettering Institute For Cancer Research Beta-Glycosyl C-Nucleoside mit anti-leukemischer Wirkung
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
JPH02256667A (ja) * 1988-12-27 1990-10-17 Masatoshi Yamato 縮合キノリン系化合物およびその製造方法
BR9101256A (pt) 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
CA2129337A1 (en) 1992-02-19 1993-09-02 Jotham W. Coe Heterocyclic compounds for enhancing antitumor activity
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ES2200039T3 (es) 1995-12-08 2004-03-01 Pfizer Inc. Derivados heterociclicos sustituidos como antagonistas de crf.
WO1997029110A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Thiophenopyrimidines
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
NZ520093A (en) * 1997-11-11 2004-03-26 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
PY0111330A (es) 2003-11-03
WO2001094353A1 (en) 2001-12-13
DE60106022T2 (de) 2006-03-09
ES2223827T3 (es) 2005-03-01
EP1287001B1 (de) 2004-09-29
JP2003535867A (ja) 2003-12-02
US20020042409A1 (en) 2002-04-11
UY26750A1 (es) 2002-01-31
MXPA02012034A (es) 2003-04-25
AR032621A1 (es) 2003-11-19
PA8518701A1 (es) 2002-09-17
ECSP014097A (es) 2003-02-06
US6964961B2 (en) 2005-11-15
SV2002000478A (es) 2002-07-03
EP1287001A1 (de) 2003-03-05
PE20011373A1 (es) 2002-01-18
DOP2001000170A (es) 2002-05-15
AU2001252463A1 (en) 2001-12-17
DE60106022D1 (de) 2004-11-04
GT200100104A (es) 2002-01-31
CA2411084A1 (en) 2001-12-13
TR200402656T4 (tr) 2004-11-22
TNSN01082A1 (fr) 2005-11-10
PT1287001E (pt) 2004-12-31
BR0111377A (pt) 2003-06-03

Similar Documents

Publication Publication Date Title
ATE277933T1 (de) Thiophenverbindungen zur verwendung als antikrebsmittel
DE60115937D1 (de) Piperidinverbindungen zur verwendung als antiallergika
ATE485272T1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
NO20032585L (no) ABCA-1 forhoyende forbindelser
NO20026253L (no) Organiske forbindelser
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
EE200200475A (et) Arüülkondenseerunud asapolütsüklilised ühendid
EE200200082A (et) Uued spiroühendid
IS6024A (is) Ný efnasambönd
IS6239A (is) Ný efnasambönd
AR027983A1 (es) Novedosos compuestos
IS6139A (is) Ný efnasambönd
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
DE50107230D1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
PT1299356E (pt) Novos compostos
AR028220A1 (es) Novedosos compuestos
ATE372338T1 (de) Deshalogenverbindungen
NO20030303D0 (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
AR028399A1 (es) Nuevos compuestos
SE0003203D0 (sv) Novel compounds
SE0003641D0 (sv) Novel compounds
SE0000620D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287001

Country of ref document: EP

REN Ceased due to non-payment of the annual fee